The Effect of Rebamipide for Non-steroidal Anti-inflammatory Drugs (NSAID) - Induced Small-intestinal Injuries

• Status: Unknown status
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of rebamipide for NSAID-induced small-intestinal injuries.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nagoya University
• Treatments: Anti-Inflammatory Agents, Non-Steroidal; Rebamipide

Criteria

Inclusion Criteria:

• Written informed consent

• 20 to 85 years of age

• RA, OA, or low back pain

• No change of drugs before 3 months

• Under 5 mg of corticosteroid use

• CRP < 1mg/dl

• Small-intestinal mucosal injuries more than one

• Hemoglobin level is below normal range

Exclusion Criteria:

• Known or suspected small-bowel disease, including Crohn's disease and seronegative arthritis

• Prostaglandins, metronidazole or salazosulfapyridine

• Can not swallow

• Eith pacemaker

• After gastrointestinal operation

• Serious concomitant cardiovascular, endocrine, gastrointestinal(including symptoms of ileus), neurologic, psychiatric, renal, or respiratory disease.

• Taking rebamipide before one week

• Any other conditions that the investigator feels would interfere with data interpretation or create under risk.